Literature DB >> 25571865

First evidence of neosaxitoxin as a long-acting pain blocker in bladder pain syndrome.

Valentin Manríquez1, Daniela Castro Caperan, Rodrigo Guzmán, Michel Naser, Veronica Iglesia, Nestor Lagos.   

Abstract

INTRODUCTION AND HYPOTHESIS: Neosaxitoxin is a phycotoxin whose molecular mechanism of action shows a reversible inhibition of voltage-gated sodium channels at the axonal level, impeding nerve impulse propagation. This study was designed to evaluate the clinical efficacy of neosaxitoxin as a long-acting pain blocker in the treatment of bladder pain syndrome (BPS).
METHODS: Five patients with a diagnosis of BPS received a total dose of 80 µg of neosaxitoxin in an isoosmotic solution of 0.9 % NaCl, pH 6.5. Infiltration was performed via cystoscopy under spinal anesthesia. Questionnaires were administered immediately before and 7, 30 and 90 days after the procedure to measure the patients' reported pain severity and quality of life.
RESULTS: This study, for the first time, showed the effect of blocking the neuronal transmission of pain by local infiltration of neosaxitoxin into the bladder submucosa. All five patients successfully responded to the treatment. Furthermore, the analgesic effect lasted for the entire 90 days of follow-up without the need for a second infiltration, and no adverse reactions to neosaxitoxin were detected.
CONCLUSIONS: Neosaxitoxin infiltration was shown to be a safe and effective intervention to control pain related to BPS. It was well tolerated by patients, who experienced extended pain relief and associated beneficial effects over a follow-up of 90 days. These results confirm the effectiveness of neosaxitoxin as a long-acting local pain blocker.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25571865     DOI: 10.1007/s00192-014-2608-2

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  26 in total

1.  Comparison of neosaxitoxin versus bupivacaine via port infiltration for postoperative analgesia following laparoscopic cholecystectomy: a randomized, double-blind trial.

Authors:  Alberto J Rodríguez-Navarro; Charles B Berde; Gonzalo Wiedmaier; Andres Mercado; Carlos Garcia; Veronica Iglesias; David Zurakowski
Journal:  Reg Anesth Pain Med       Date:  2011 Mar-Apr       Impact factor: 6.288

2.  The relationship between fibromyalgia and interstitial cystitis.

Authors:  D J Clauw; M Schmidt; D Radulovic; A Singer; P Katz; J Bresette
Journal:  J Psychiatr Res       Date:  1997 Jan-Feb       Impact factor: 4.791

3.  The interstitial cystitis symptom index and problem index.

Authors:  M P O'Leary; G R Sant; F J Fowler; K E Whitmore; J Spolarich-Kroll
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

Review 4.  Interstitial cystitis/bladder pain syndrome: diagnosis and management.

Authors:  I Offiah; S B McMahon; B A O'Reilly
Journal:  Int Urogynecol J       Date:  2013-02-22       Impact factor: 2.894

5.  Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes.

Authors:  M Alagiri; S Chottiner; V Ratner; D Slade; P M Hanno
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

6.  Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up.

Authors:  Yahya Q Ghazwani; Mohamed S Elkelini; Magdy M Hassouna
Journal:  Neurourol Urodyn       Date:  2011-05-06       Impact factor: 2.696

7.  Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative.

Authors:  Josefine Rössberger; Magnus Fall; Olof Jonsson; Ralph Peeker
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

8.  A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis.

Authors:  Kenneth M Peters; Kevin M Feber; Richard C Bennett
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

9.  Potentiation of local anesthetic activity of neosaxitoxin with bupivacaine or epinephrine: development of a long-acting pain blocker.

Authors:  Alberto J Rodriguez-Navarro; Marcelo Lagos; Cristian Figueroa; Carlos Garcia; Pedro Recabal; Pamela Silva; Veronica Iglesias; Nestor Lagos
Journal:  Neurotox Res       Date:  2009-07-28       Impact factor: 3.911

10.  Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy.

Authors:  Kinue Aihara; Akihide Hirayama; Nobumichi Tanaka; Kiyohide Fujimoto; Kastunori Yoshida; Yoshihiko Hirao
Journal:  Int J Urol       Date:  2009-12       Impact factor: 3.369

View more
  8 in total

Review 1.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

Review 2.  Voltage-gated sodium channels: (NaV )igating the field to determine their contribution to visceral nociception.

Authors:  Andelain Erickson; Annemie Deiteren; Andrea M Harrington; Sonia Garcia-Caraballo; Joel Castro; Ashlee Caldwell; Luke Grundy; Stuart M Brierley
Journal:  J Physiol       Date:  2018-02-06       Impact factor: 5.182

3.  Dinoflagellate Phosphopantetheinyl Transferase (PPTase) and Thiolation Domain Interactions Characterized Using a Modified Indigoidine Synthesizing Reporter.

Authors:  Ernest Williams; Tsvetan Bachvaroff; Allen Place
Journal:  Microorganisms       Date:  2022-03-23

Review 4.  Industrial Applications of Dinoflagellate Phycotoxins Based on Their Modes of Action: A Review.

Authors:  Kichul Cho; Jina Heo; Jinwook Han; Hyun Dae Hong; Hancheol Jeon; Hyun-Ju Hwang; Chang-Yu Hong; Daekyung Kim; Jong Won Han; Kyunghwa Baek
Journal:  Toxins (Basel)       Date:  2020-12-18       Impact factor: 4.546

Review 5.  Voltage-Gated Sodium Channels: A Prominent Target of Marine Toxins.

Authors:  Rawan Mackieh; Rita Abou-Nader; Rim Wehbe; César Mattei; Christian Legros; Ziad Fajloun; Jean Marc Sabatier
Journal:  Mar Drugs       Date:  2021-10-05       Impact factor: 5.118

Review 6.  Guanidinium Toxins and Their Interactions with Voltage-Gated Sodium Ion Channels.

Authors:  Lorena M Durán-Riveroll; Allan D Cembella
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

Review 7.  Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders.

Authors:  Andreina Baj; Michela Bistoletti; Annalisa Bosi; Elisabetta Moro; Cristina Giaroni; Francesca Crema
Journal:  Toxins (Basel)       Date:  2019-07-31       Impact factor: 4.546

Review 8.  An Updated Review of Tetrodotoxin and Its Peculiarities.

Authors:  Panagiota Katikou; Cengiz Gokbulut; Ali Rıza Kosker; Mònica Campàs; Fatih Ozogul
Journal:  Mar Drugs       Date:  2022-01-03       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.